Company Description
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.
It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver.
It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers’ diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection.
The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products.
The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008.
Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
| Country | Australia |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Steven Lydeamore |
Contact Details
Address: 62 Lygon Street, Level 3 Carlton, VIC 3053 Australia | |
| Phone | 61 3 9824 5254 |
| Website | immuron.com.au |
Stock Details
| Ticker Symbol | IMRN |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| CIK Code | 0001660046 |
| CUSIP Number | 45254U101 |
| ISIN Number | US45254U1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steven George Lydeamore CPA, M.B.A. | Chief Executive Officer |
| Dr. Jerry Kanellos Ph.D. | Chief Operating Officer |
| Flavio Palumbo | Chief Commercial Officer |
| Phillip Allen Hains BBus(Acc), C.A., M.B.A. | Chief Financial Officer and Company Secretary |
| David Lyon | Head of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | 6-K | Report of foreign issuer |
| Oct 29, 2024 | 6-K | Report of foreign issuer |
| Oct 18, 2024 | 6-K | Report of foreign issuer |
| Oct 16, 2024 | 6-K | Report of foreign issuer |
| Oct 15, 2024 | 6-K | Report of foreign issuer |
| Oct 8, 2024 | 6-K | Report of foreign issuer |
| Oct 4, 2024 | 6-K | Report of foreign issuer |
| Oct 1, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Sep 26, 2024 | 6-K | Report of foreign issuer |